Skip to content

This website is a third-party information service. It does not provide medical care or operate a treatment facility.

Colorectal Biologic Trials

Ohio

Colorectal cancer biologic therapy trials in Ohio

10 colorectal cancer biologic therapy studies are recruiting participants at sites in 16 cities across Ohio as of November 18, 2026, according to ClinicalTrials.gov.

Call (888) 413-6546
  • No cost to ask
  • Taking part is voluntary
  • Studies are independently reviewed

Browse Ohio by city

Cities with the most studies recruiting right now.

Every Ohio city with a recruiting study

Cincinnati (5), Cleveland (4), Columbus (3), Canton (2), Akron (1), Centerville (1), Fairfield (1), Independence (1), Mansfield (1), Mayfield Heights (1), Sandusky (1), Strongsville (1), Toledo (1), Warrensville Heights (1), Wooster (1), Youngstown (1).

The number after each city is how many studies have a recruiting site there. A study with sites in several cities is counted in each one.

Recently updated studies in Ohio

Basic details from each study's public record. Select a study to read the full record on ClinicalTrials.gov, including how to contact its team.

  1. Testing Pump Chemotherapy in Addition to Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone for Patients With Unresectable Colorectal Liver Metastases: The PUMP Trial

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    ECOG-ACRIN Cancer Research Group
    Recruiting in
    Columbus · Youngstown
    Registry record
    NCT05863195 · updated
  2. A Clinical Study of Calderasib (MK-1084) With Targeted Therapy and Chemotherapy in People With Colorectal Cancer (MK-1084-012/KANDLELIT-012)

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Merck Sharp & Dohme LLC
    Recruiting in
    Centerville · Cincinnati · Toledo
    Registry record
    NCT06997497 · updated
  3. Testing the Addition of Anti-cancer Drug, ZEN003694, to the Usual Chemotherapy Treatment, Cetuximab Plus Encorafenib, for Colorectal Cancer

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Recruiting in
    Columbus
    Registry record
    NCT06102902 · updated
  4. A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Janssen Research & Development, LLC
    Recruiting in
    Canton · Cleveland · Independence · and 6 more U.S. locations
    Registry record
    NCT06662786 · updated
  5. A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Janssen Research & Development, LLC
    Recruiting in
    Canton · Cleveland
    Registry record
    NCT06750094 · updated
  6. Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Pfizer
    Recruiting in
    Cincinnati · Cleveland · Fairfield
    Registry record
    NCT07222800 · updated
  7. A Phase 1 Study Evaluating DISP-10 in Participants With Advanced Gastrointestinal Cancers

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    Dispatch Biotherapeutics
    Recruiting in
    Cincinnati
    Registry record
    NCT07544589 · updated
  8. Study of XmAb®819 in Subjects With Advanced Clear Cell Renal Cell Carcinoma

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    Xencor, Inc.
    Recruiting in
    Cincinnati · Columbus
    Registry record
    NCT05433142 · updated
  9. A Clinical Study to Test if an Investigational Treatment Called BNT314 When Used in Combination With Another Investigational Treatment Pumitamig (BNT327) and Chemotherapy, is Beneficial and Safe for Patients With Advanced Colorectal Cancer

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    BioNTech SE
    Recruiting in
    Cleveland
    Registry record
    NCT07079631 · updated
  10. Study of Perioperative Dostarlimab in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    GlaxoSmithKline
    Recruiting in
    Akron · Cincinnati
    Registry record
    NCT05855200 · updated

Source: ClinicalTrials.gov. Data processed . See every colorectal cancer study recruiting in Ohio on ClinicalTrials.gov.

Ask about studies in Ohio

Tell us what you are looking for and a coordinator will contact you to talk through your options. Asking does not commit you to anything.

How should we reach you?
Add a message or the best time to reach you (optional)

Please do not include detailed medical information.

Before you contact a study

About these listings

These listings come from ClinicalTrials.gov, the study registry run by the U.S. National Library of Medicine. The data were processed on November 18, 2026. We show part of each public record (its title, phase, sponsor, basic eligibility and sites in this area) exactly as registered, and we group studies by place. Nothing in a record is reworded. This site lists only studies that test a biologic, such as a vaccine, an antibody, or a cell or gene therapy, as each study is coded in the registry.

Colorectal Biologic Trials does not run these studies and is not affiliated with their sponsors. A listing is not a recommendation, and only a study's own team can tell you whether you may be eligible. Follow the link on any study to read its full record and contact that team directly, or ask us and a coordinator will help you understand your options. How we source and check what we publish.

Sources and further reading

Ask about a study

A coordinator will contact you. Asking does not commit you to anything.

Call (888) 413-6546

or send a short form

How should we reach you?

Call